Racial Disparity in Response to Prostate Cancer Systemic Therapies

被引：13

作者：

Bitting, Rhonda L. ^{[1
,2
]}

Goodman, Michael ^{[3
,4
]}

George, Daniel J. ^{[2
]}

机构：

[1] Durham VA Hlth Care Syst, Durham, NC 27705 USA

[2] Duke Univ, Duke Canc Inst, Ctr Prostate & Urol Canc, Duke Box 103861, Durham, NC 27710 USA

[3] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27101 USA

[4] WG Bill Hefner VA Med Ctr, 1601 Brenner Ave, Salisbury, NC 28144 USA

来源：

CURRENT ONCOLOGY REPORTS | 2020年 / 22卷 / 09期

关键词：

Metastatic prostate cancer; Racial disparities; African Americans; CRPC; Sipuleucel-T; Docetaxel; Abiraterone; AFRICAN-AMERICAN; SIPULEUCEL-T; SURVIVAL; MITOXANTRONE; ABIRATERONE; PREDNISONE; TRIALS; TUMORS; MEN;

D O I：

10.1007/s11912-020-00966-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). Recent Findings Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer. This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.

引用

页数：5

共 32 条

[1] The Molecular Taxonomy of Primary Prostate Cancer [J].

Abeshouse, Adam ;

Ahn, Jaeil ;

Akbani, Rehan ;

Ally, Adrian ;

Amin, Samirkumar ;

Andry, Christopher D. ;

Annala, Matti ;

Aprikian, Armen ;

Armenia, Joshua ;

Arora, Arshi ;

Auman, J. Todd ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barbieri, Christopher E. ;

Bauer, Thomas ;

Benz, Christopher C. ;

Bergeron, Alain ;

Beroukhim, Rameen ;

Berrios, Mario ;

Bivol, Adrian ;

Bodenheimer, Tom ;

Boice, Lori ;

Bootwalla, Moiz S. ;

dos Reis, Rodolfo Borges ;

Boutros, Paul C. ;

Bowen, Jay ;

Bowlby, Reanne ;

Boyd, Jeffrey ;

Bradley, Robert K. ;

Breggia, Anne ;

Brimo, Fadi ;

Bristow, Christopher A. ;

Brooks, Denise ;

Broom, Bradley M. ;

Bryce, Alan H. ;

Bubley, Glenn ;

Burks, Eric ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Canes, David ;

Carlotti, Carlos G. ;

Carlsen, Rebecca ;

Carmel, Michel ;

Carroll, Peter R. ;

Carter, Scott L. ;

Cartun, Richard ;

Carver, Brett S. ;

Chan, June M. ;

Chang, Matthew T. ;

Chen, Yu .

CELL, 2015, 163 (04) :1011-1025

[2] Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group [J].

Albain, Kathy S. ;

Unger, Joseph M. ;

Crowley, John J. ;

Coltman, Charles A., Jr. ;

Hershman, Dawn L. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (14) :984-992

[3] The Tuskegee Study of Untreated Syphilis: A Case Study in Peripheral Trauma with Implications for Health Professionals [J].

Alsan, Marcella ;

Wanamaker, Marianne ;

Hardeman, Rachel R. .

JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (01) :322-325

[4]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[5] RACISM AND RESEARCH - CASE OF TUSKEGEE SYPHILIS STUDY [J].

BRANDT, AM .

HASTINGS CENTER REPORT, 1978, 8 (06) :21-29

[6] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[7] An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx) [J].

Efstathiou, Eleni ;

Deshpande, Hari ;

George, Daniel ;

Joshua, Anthony M. ;

Taplin, Mary-Ellen ;

Griffin, Thomas W. ;

Londhe, Anil ;

Todd, Mary ;

Molina, Arturo .

CANCER RESEARCH, 2014, 74 (19)

[8] Clinical outcomes by age in men with hormone refractory prostate cancer: A pooled analysis of 8 cancer and leukemia group B (CALGB) studies [J].

Halabi, S ;

Vogelzang, NJ ;

Ou, SS ;

Kelly, WK ;

Small, EJ .

JOURNAL OF UROLOGY, 2006, 176 (01) :81-86

[9] Pain predicts overall survival in men with metastatic castration-refractory prostate cancer [J].

Halabi, Susan ;

Vogelzang, Nicholas J. ;

Kornblith, Alice B. ;

Ou, San-San ;

Kantoff, Philip W. ;

Dawson, Nancy A. ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2544-2549

[10] Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel [J].

Halabi, Susan ;

Dutta, Sandipan ;

Tangen, Catherine M. ;

Rosenthal, Mark ;

Petrylak, Daniel P. ;

Thompson, Ian M. ;

Chi, Kim N. ;

Araujo, John C. ;

Logothetis, Christopher ;

Quinn, David I. ;

Fizazi, Karim ;

Morris, Michael J. ;

Eisenberger, Mario A. ;

George, Daniel J. ;

De Bono, Johann S. ;

Higano, Celestia S. ;

Tannock, Ian F. ;

Small, Eric J. ;

Kelly, William Kevin .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) :403-+

← 1 2 3 4 →